Hematology-Oncology Fellowship

The Division of Hematology-Oncology offers a combined three-year fellowship program, allowing trainees to be eligible for board certification in both disciplines. Hematology-Oncology fellows also have the option of pursuing a two-year program in one of the two subspecialties. The program is designed to meet the individual needs and interests of each fellow. The Hematology-Oncology Fellowship Program at IU School of Medicine has received the highest level of accreditation by the ACGME with a maximum cycle length of five years.

Program Components

Clinical Training

The first year is the clinical year, consisting of rotations through the various clinical services, including inpatient hematology, oncology, bone marrow transplantation, and consult services in hematology and oncology at IU Health University Hospital, Eskenazi Health and the Richard L. Roudebush VA Medical Center. Patient care activities at IU School of Medicine take place at the IU Health Simon Cancer Center or at the adjacent IU Health University Hospital.

Research Experience

The second and third years of the program allow for fellows to complete additional clinical rotations, but the focus of these years is primarily on gaining research experience. Fellows are assigned an adviser during their first year, and a formal mentor during the second and third years. Large blocks of time are designated for laboratory of clinical research; these academic and scholarly activities are an integral part of the training program. It is expected that during these years, each fellow will accomplish sufficient, high-quality clinical or basic science research with the goal of presenting at least one national meeting, and submitting for a peer-reviewed publication. National meetings include the American Society of Clinical Oncology, the American Association for Cancer Research and the American Society of Hematology.

The specific laboratory and clinical research activities within the division are numerous. Fellows have achieved success in contributing to the understanding and management of various forms of cancer. Every fellow is expected to engage in a mentored research project during their training. Active research programs exist in tumor biology, hematopoiesis, signal transduction, pharmacogenomics and molecular biology. A new research facility houses the Walther Cancer Institute, which is directed by Hal Broxmeyer, PhD. The Division of Hematology/Oncology belongs to a number of cooperative research groups, including the Eastern Cooperative Oncology Group, the Gynecological Oncology Group, the Radiation Therapy Oncology Group, the Hoosier Cancer Research Network, the Children’s Cancer Study Group, and the Children’s Oncology Group.

Continuity of Care

Each fellow has a continuity of care clinic throughout their three-year fellowship. This includes a hematology clinic and an oncology clinic at the Richard L. Roudebush VA Medical Center or Eskenazi Health. In addition, each fellow participates in rotating three-month subspecialty clinics throughout the duration of the program. Subspecialty care includes multidisciplinary care clinics for breast, thoracic, gastrointestinal and genitourinary cancers as well as leukemia, lymphoma and benign hematology. Additional clinics are available and include sarcoma, renal cancer, melanoma, head and neck cancer, myeloma, bone marrow transplantation, gynecological cancer, testicular cancer, and radiation oncology. While rotation on the inpatient and consult services at IU Health University Hospital, Eskenazi Health or the VA, the fellow plays a prominent role as the junior attending, supervised by a faculty physician.


In addition to clinical and research activities and responsibilities, formal conferences are considered to be a central part of the fellow’s education. Each subspecialty has a weekly multidisciplinary conference. Weekly conferences in both hematology and oncology are organized by fellows and are supervised by faculty. A monthly Journal Club enhances fellows’ ability to critique relevant articles from current literature.